{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:02:03Z","timestamp":1793826123293,"version":"4.6.1"},"reference-count":52,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Duke Kunshan University Startup Fund","award":["00AKUG0130"],"award-info":[{"award-number":["00AKUG0130"]}]},{"award":["00AKUG0130"],"award-info":[{"award-number":["00AKUG0130"]}],"id":[{"id":"https:\/\/ror.org\/04sr5ys16","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Two chikungunya (CHIKV) vaccines have now been licensed, but the human clinical evidence base remains fragmented across vaccine platforms, populations, follow-up periods, and safety settings, complicating product-specific interpretation of durability and benefit\u2013risk. We conducted a PRISMA-ScR\u2013guided scoping review of human CHIKV vaccine evidence indexed in PubMed, Embase, and Web of Science from January 2000 to June 2026. After screening 890 records, we included 77 sources of evidence and mapped them at both the record level and the candidate\/product level. The included evidence clustered around a limited number of vaccine programs, including TSI-GSD-218, VRC-CHKVLP059-00-VP\/PXVX0317\/Vimkunya, MV-CHIK\/V184, VLA1553\/IXCHIQ, ChAdOx1 Chik, and mRNA-1388\/VAL-181388. Late-stage and post-authorization evidence was concentrated mainly in VLA1553\/IXCHIQ and PXVX0317\/Vimkunya, whereas viral-vector and mRNA candidates remained largely restricted to early-phase adult studies. Evidence has expanded to adolescents and adults aged \u226565 years for selected products but remains limited or product-specific for children, pregnant individuals, immunocompromised populations, and medically complex older adults. Short-term trial safety data were characterized primarily by mild or moderate local and systemic reactogenicity, while post-authorization safety evidence remains recent and concentrated in licensed products. This scoping review provides a structured evidence map for CHIKV vaccine development and highlights priorities for standardized immunogenicity assessment, longer-term durability data, broader population representation, endemic-region effectiveness studies, and continued post-marketing surveillance.<\/jats:p>","DOI":"10.3390\/vaccines14070598","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:43:14Z","timestamp":1783345394000},"page":"598","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mapping Human Clinical Evidence for Chikungunya Vaccines: A Scoping Review of Immunogenicity, Durability, and Safety"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4986-7633","authenticated-orcid":false,"given":"Shan","family":"Wu","sequence":"first","affiliation":[{"name":"Division of Natural and Applied Science, Duke Kunshan University, Kunshan 215316, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0957-1877","authenticated-orcid":false,"given":"Jiachen","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Natural and Applied Science, Duke Kunshan University, Kunshan 215316, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8360-9537","authenticated-orcid":false,"given":"Yiu-Wing","family":"Kam","sequence":"additional","affiliation":[{"name":"Division of Natural and Applied Science, Duke Kunshan University, Kunshan 215316, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijid.2017.03.006","article-title":"Global expansion of chikungunya virus: Mapping the 64-year history","volume":"58","author":"Wahid","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Martelossi-Cebinelli, G., Carneiro, J.A., Yaekashi, K.M., Bertozzi, M.M., Bianchini, B.H.S., Rasquel-Oliveira, F.S., Zanluca, C., Duarte Dos Santos, C.N., Arredondo, R., and Blackburn, T.A. (2025). A Review of the Biology of Chikungunya Virus Highlighting the Development of Current Novel Therapeutic and Prevention Approaches. Pathogens, 14.","DOI":"10.3390\/pathogens14101047"},{"key":"ref_3","unstructured":"Centers for Disease Control and Prevention (2026, June 25). Clinical Testing and Diagnosis for Chikungunya Virus Disease, Available online: https:\/\/www.cdc.gov\/chikungunya\/hcp\/diagnosis-testing\/index.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.virol.2009.07.024","article-title":"Replication cycle of chikungunya: A re-emerging arbovirus","volume":"393","author":"Solignat","year":"2009","journal-title":"Virology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nature09555","article-title":"Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography","volume":"468","author":"Voss","year":"2010","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tsetsarkin, K.A., McGee, C.E., Volk, S.M., Vanlandingham, D.L., Weaver, S.C., and Higgs, S. (2009). Epistatic roles of E2 glycoprotein mutations in adaption of chikungunya virus to Aedes albopictus and Ae. aegypti mosquitoes. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006835"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jama.2020.2477","article-title":"Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes A Randomized Clinical Trial","volume":"323","author":"Chen","year":"2020","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.antiviral.2013.06.009","article-title":"Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy","volume":"99","author":"Thiberville","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4103\/0019-5154.60355","article-title":"Epidemiology, clinical manifestations, and diagnosis of Chikungunya fever: Lessons learned from the re-emerging epidemic","volume":"55","author":"Mohan","year":"2010","journal-title":"Indian J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.4103\/0971-5916.176637","article-title":"Chikungunya outbreak in Atmakur village, Medak district, Telangana State, India","volume":"142","author":"Uthappa","year":"2015","journal-title":"Indian J. Med. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S471","DOI":"10.1093\/infdis\/jiw274","article-title":"Laboratory Diagnosis of Chikungunya Virus Infections and Commercial Sources for Diagnostic Assays","volume":"214","author":"Johnson","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_12","unstructured":"Ojeda Rodriguez, J.A., Haftel, A., and Walker, I.J. (2026). Chikungunya Fever. StatPearls, StatPearls Publishing."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/acr.22900","article-title":"Prevalence of Post-Chikungunya Infection Chronic Inflammatory Arthritis: A Systematic Review and Meta-Analysis","volume":"68","year":"2016","journal-title":"Arthritis Care Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lee, V.J., Chow, A., Zheng, X., Carrasco, L.R., Cook, A.R., Lye, D.C., Ng, L.C., and Leo, Y.S. (2012). Simple clinical and laboratory predictors of Chikungunya versus dengue infections in adults. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001786"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rueda, J.C., Pel\u00e1ez-Ballestas, I., Angarita, J.I., Santos, A.M., Pinzon, C., Saldarriaga, E.L., Rueda, J.M., Forero, E., Saaibi, D.L., and Pav\u00eda, P.X. (2023). Clinical Diagnosis of Chikungunya Infection: An Essential Aid in a Primary Care Setting Where Serological Confirmation Is Not Available. Trop. Med. Infect. Dis., 8.","DOI":"10.20944\/preprints202303.0109.v1"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12038-008-0063-2","article-title":"Chikungunya: An overview","volume":"33","author":"Sudeep","year":"2008","journal-title":"J. Biosci."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Rosso, A., Flacco, M.E., Cioni, G., Tiseo, M., Imperiali, G., Bianconi, A., Fiore, M., Cal\u00f2, G.L., Orazi, V., and Troia, A. (2024). Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis. Vaccines, 12.","DOI":"10.3390\/vaccines12090969"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(25)00372-1","article-title":"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: A phase randomised, double-blind, placebo-controlled trial","volume":"405","author":"Tindale","year":"2025","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","article-title":"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: A double-blind, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"401","author":"Schneider","year":"2023","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0140-6736(25)00345-9","article-title":"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: A phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Richardson","year":"2025","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"128491","DOI":"10.1016\/j.vaccine.2026.128491","article-title":"Post-marketing safety evaluation of the live-attenuated chikungunya vaccine (IXCHIQ)","volume":"79","author":"Vondeling","year":"2026","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4269\/ajtmh.2000.62.681","article-title":"Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218","volume":"62","author":"Edelman","year":"2000","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S1473-3099(22)00226-2","article-title":"Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: A randomised, double-blind, parallel-group, phase 2 trial","volume":"22","author":"Bennett","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/S0140-6736(14)61185-5","article-title":"Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: A phase 1 dose-escalation trial","volume":"384","author":"Chang","year":"2014","journal-title":"Lancet"},{"key":"ref_26","first-page":"199","article-title":"A virus-like particle vaccine elicits broad neutralizing antibody responses in humans against distinct chikungunya virus genotypes","volume":"95","author":"Goo","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101000","DOI":"10.1016\/j.lanmic.2024.101000","article-title":"Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: An open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled study","volume":"6","author":"Hamer","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1016\/j.vaccine.2023.08.086","article-title":"Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals","volume":"41","author":"McCarty","year":"2023","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"eade8273","DOI":"10.1126\/scitranslmed.ade8273","article-title":"A chikungunya virus-like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans","volume":"15","author":"Raju","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_30","unstructured":"(2026, July 02). VRC 311: A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Virus-Like Particle (VLP) Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults. Identifier: NCT01489358, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01489358."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: A randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: A double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2019","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1016\/j.vaccine.2023.09.022","article-title":"A measles virus-based vaccine induces robust chikungunya virus-specific CD4+ T-cell responses in a phase II clinical trial","volume":"41","author":"Schmitz","year":"2023","journal-title":"Vaccine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1093\/infdis\/jiaf571","article-title":"A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults","volume":"233","author":"Winokur","year":"2026","journal-title":"J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"taae084","DOI":"10.1093\/jtm\/taae084","article-title":"Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine","volume":"31","author":"Buerger","year":"2024","journal-title":"J. Travel Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1473-3099(25)00631-0","article-title":"Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: Final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil","volume":"26","author":"Buerger","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"taae133","DOI":"10.1093\/jtm\/taae133","article-title":"Pooled safety evaluation for a new single-shot live-attenuated chikungunya vaccine","volume":"31","author":"Maurer","year":"2024","journal-title":"J. Travel Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"taad156","DOI":"10.1093\/jtm\/taad156","article-title":"A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults","volume":"31","author":"McMahon","year":"2024","journal-title":"J. Travel Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S1473-3099(24)00357-8","article-title":"Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: A single-arm multicentre, phase 3b study","volume":"24","author":"McMahon","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"128787","DOI":"10.1016\/j.vaccine.2026.128787","article-title":"Chikungunya virus-neutralizing antibody persistence four years after single-dose vaccination with VLA1553 (IXCHIQ\u00ae)","volume":"88","author":"Sattler","year":"2026","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41591-025-04197-2","article-title":"Live-attenuated chikungunya vaccine in children: A randomized phase 2 trial","volume":"32","author":"Scheiblauer","year":"2026","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(20)30238-3","article-title":"Single-shot live-attenuated chikungunya vaccine in healthy adults: A phase 1, randomised controlled trial","volume":"20","author":"Wressnigg","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1038\/s41467-021-24906-y","article-title":"A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial","volume":"12","author":"Folegatti","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1016\/j.vaccine.2023.04.064","article-title":"A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults","volume":"41","author":"Shaw","year":"2023","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1473-3099(24)00458-4","article-title":"Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: Interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents","volume":"25","author":"Buerger","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_46","unstructured":"European Medicines Agency (2025). EU Risk Management Plan: VIMKUNYA (Chikungunya Vaccine, Recombinant, Adsorbed), European Medicines Agency."},{"key":"ref_47","first-page":"202","article-title":"Phase 2 clinical results\u2014Chikungunya vaccine based on measles vector (MV-CHIK) induces humoral and cellular responses in the presence of pre-existing anti measles immunity","volume":"99","author":"Ramsauer","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S488","DOI":"10.1093\/infdis\/jiw271","article-title":"Development of Vaccines for Chikungunya Fever","volume":"214","author":"Erasmus","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.2147\/DDDT.S181574","article-title":"Recent development in the strategies projected for chikungunya vaccine in humans","volume":"12","author":"Goyal","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40259-024-00677-y","article-title":"Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure","volume":"38","author":"Weber","year":"2024","journal-title":"BioDrugs"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2500792","DOI":"10.2807\/1560-7917.ES.2025.30.44.2500792","article-title":"Post-authorisation experience and reported adverse events following use of a virus-like particle chikungunya vaccine, United States and Germany, up to August 2025","volume":"30","author":"Simone","year":"2025","journal-title":"Euro Surveill."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2500543","DOI":"10.2807\/1560-7917.ES.2025.30.32.2500543","article-title":"Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025","volume":"30","author":"Hills","year":"2025","journal-title":"Euro Surveill."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/598\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:30:43Z","timestamp":1783348243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["vaccines14070598"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14070598","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}